- Molecular NameVoriconazole
- SynonymVCZ; voriconazole
- Weight349.316
- Drugbank_IDDB00582
- ACS_NO137234-62-9
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.62
- pkaN/A
- LogD (pH=7, predicted)1.62
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-3.95
- LogSw (predicted, AB/LogsW2.0)0.45
- Sw (mg/ml) (predicted, ACD/Labs)0.04
- No.of HBond Donors1
- No.of HBond Acceptors6
- No.of Rotatable Bonds5
- TPSA76.72
- StatusFDA approved
- AdministrationIV, oral
- PharmacologyA triazole antifungal medication that is generally used to treat serious, invasive fungal infections. These are generally seen in patients who are immunocompromised, and include invasive candidiasis, invasive aspergillosis, and certain emerging fungal infections.
- Absorption_value96.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability96.0
- Protein binding58.0
- Volume of distribution (VD)1.6 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolized mainly to an inactive N-oxide by CYP2C19 (major), CYP3A4, and CYP2C9.
- Half life6.7 h
- ExcretionN/A
- Urinary Excretion<2
- Clerance3.8 ml/min/kg
- ToxicityThe minimum lethal oral dose in mice and rats was 300 mg/kg (equivalent to 4 and 7 times the recommended maintenance dose (RMD), based on body surface area). At this dose, clinical signs observed in both mice and rats included salivation, mydriasis, titubation (loss of balance while moving), depressed behavior, prostration, partially closed eyes, and dyspnea. Other signs in mice were convulsions, corneal opacification and swollen abdomen.
- LD50 (rat)N/A
- LD50 (mouse)N/A